Abstract

You have accessJournal of UrologyCME1 May 2022MP55-15 CAN MRI LOCALIZE THE PROXIMITY OF PROSTATE CANCER TO THE URETHRA IN MEN WHO ARE CANDIDATES FOR FOCAL GLAND ABLATION? Neal Patel, Alexa Hughes, Wayne Brisbane, Ali Rastegarpour, Sohrab Afshari, Lorna Kwan, Anissa V. Nguyen, Anthony Sisk, Steven Raman, and Robert Reiter Neal PatelNeal Patel More articles by this author , Alexa HughesAlexa Hughes More articles by this author , Wayne BrisbaneWayne Brisbane More articles by this author , Ali RastegarpourAli Rastegarpour More articles by this author , Sohrab AfshariSohrab Afshari More articles by this author , Lorna KwanLorna Kwan More articles by this author , Anissa V. NguyenAnissa V. Nguyen More articles by this author , Anthony SiskAnthony Sisk More articles by this author , Steven RamanSteven Raman More articles by this author , and Robert ReiterRobert Reiter More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002634.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Despite improvements in the localization of prostate cancer with magnetic resonance imaging, appropriate patient selection for focal ablation of prostate cancer remains a challenge. Given that certain focal therapies minimize side effects by preserving prostate tissue near the urethra, in this study, we aim to determine whether prostate MRI could accurately identify the distance of prostate cancer to the urethra in a cohort of men who were potential candidates for focal gland ablation. METHODS: A retrospective, single-institution analysis of men who underwent an MRI, targeted biopsy, had a subsequent radical prostatectomy and were candidates for focal gland ablation based on pre-treatment risk stratification (intermediate Gleason grade, PSA <20, single MRI visible lesion) was performed. The ability of MRI to identify lesions that were within 5 mm of the prostatic urethra on whole-mount pathology was determined. Multivariable regression was utilized to determine clinical characteristics associated with having prostate cancer within 5 mm of the urethra. RESULTS: A total of 90 patients were identified to be candidates for focal-gland ablation. In 66 men (73.3%), the tumor was within 5 mm of the urethra on whole-mount pathology. MRI correctly identified the cancer location either within or outside a 5 mm radius of the urethra in 68 men (75.5%). The sensitivity of MRI for identifying cancer near the urethra was 78.8% (73.5-84.1%), and specificity was 66.7% (58.1-75.3%). The PPV was 86.7% (79.4-91.6%), and NPV was 53.3% (39.8-66.4%). The overall agreement was moderate (kappa=0.47). In adjusted analysis, no clinical factors (PI-RADS, PSA density, or tumor diameter) were significantly associated with having prostate cancer within close proximity of the urethra. CONCLUSIONS: A significant number of men who are potential candidates for focal ablation may have cancer close to the urethra that could serve as a significant source of infield recurrence after treatment. MRI can be used to identify these tumors and the distance from the tumor to the urethra should be calculated to improve patient selection for focal gland ablation. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e943 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Neal Patel More articles by this author Alexa Hughes More articles by this author Wayne Brisbane More articles by this author Ali Rastegarpour More articles by this author Sohrab Afshari More articles by this author Lorna Kwan More articles by this author Anissa V. Nguyen More articles by this author Anthony Sisk More articles by this author Steven Raman More articles by this author Robert Reiter More articles by this author Expand All Advertisement PDF DownloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call